Morepen Laboratories begins commercial supplies under ₹825 crore CDMO mandate

What Morepen Laboratories announced

Morepen Laboratories Limited filed a press release with the National Stock Exchange on 1 July 2026 stating that it has started commercial supplies under a contract‑development‑manufacturing‑organisation (CDMO) mandate valued at approximately Rs 825 crore. The company described the milestone as the first commercial execution of the mandate, which was secured earlier in the fiscal year.

Details of the ₹825 crore CDMO mandate

The CDMO mandate is a long‑term agreement with unnamed pharmaceutical partners for the development, scale‑up, and commercial manufacturing of finished dosage forms. While the press release does not disclose the exact product portfolio, it confirms that the contract covers multiple therapeutic segments and will utilise Morepen’s existing GMP‑certified facilities across India. The total contract value of Rs 825 crore reflects the aggregate revenue expected over the life of the agreement, including development fees and manufacturing charges.

Commercial supply rollout

According to the filing, the first batch of products under the mandate has already been dispatched to the partner’s supply chain. Morepen highlighted that the commercial supply phase will proceed in phases, aligned with the partners’ market launch schedules. The company expects the CDMO business to contribute a material share of its total revenue in the coming years, leveraging its recent capacity expansions and regulatory approvals.

Key facts at a glance

Why this matters for investors

The commencement of commercial supplies under a sizable CDMO mandate signals that Morepen’s strategic push into contract manufacturing is moving from pipeline to revenue‑generating operations. For shareholders, the key considerations are:

• Revenue diversification – CDMO earnings are less cyclical than proprietary product sales.
• Capacity utilisation – Existing plants will see higher run‑rates, potentially improving operating margins.
• Order‑book visibility – A confirmed Rs 825 crore contract provides a concrete anchor for future financial guidance. The filing does not mention any dilution, financing, or regulatory approvals required to execute the mandate, suggesting that the company can fund the operations from internal cash flows and existing working capital.

Conclusion

Morepen Laboratories has officially begun delivering products under a Rs 825 crore CDMO contract, marking the first commercial step of a broader contract‑manufacturing strategy. The announcement, filed on 1 July 2026, confirms the company’s intent to grow its CDMO revenue stream, though detailed financial impact will become clearer as the supply phases progress.

"We are pleased to commence commercial supplies under the Rs 825 crore CDMO mandate, reinforcing our commitment to become a leading contract manufacturing partner in the pharma sector," the company said in the press release.